Core Insights - PesoRama Inc. reported strong financial results for Q2 Fiscal 2026, highlighting a 20% increase in total sales and a 5% rise in same store sales, demonstrating the resilience of its business model despite currency challenges [2][5][6] Financial Performance - Total sales increased by 20% in 2025 compared to 2024, reaching approximately $6,097,750 [5][6] - Product gross margins improved by 3.2%, rising to 46% from 42.8% due to a decrease in per unit inventory costs [5][6] - Average ticket size increased by 20.2%, reflecting heightened demand and an expanded product assortment [2][5][6] - Same store sales grew by 5% in 2025 compared to 2024, indicating strong customer demand and effective execution at existing locations [5][6] Expansion and Growth Strategy - The company successfully closed a $6.8 million oversubscribed equity financing to support its growth strategy and store expansion [2][5][6] - PesoRama opened three new stores in 2025, bringing the total to 28 locations, which are strategically placed in high-density, high-traffic areas [6][8]

Core Viewpoint - Lion One Metals Limited successfully closed an upsized non-brokered private placement, raising gross proceeds of $18.7 million to fund the development of its Tuvatu Gold Project and other financial obligations [1][2]. Group 1: Offering Details - The LIFE Offering raised gross proceeds of $18,715,153 through the issuance of 58,484,853 units at a price of $0.32 per unit, each consisting of one common share and one warrant [1]. - Each warrant allows the holder to acquire one common share at an exercise price of $0.42 for three years from issuance [1]. - The company paid finder's fees totaling $703,468.15 in cash and issued 2,190,462 finders warrants, representing a 7% commission on gross proceeds [3]. Group 2: Use of Proceeds - The net proceeds from the LIFE Offering will be allocated to the development of the Tuvatu Gold Project, repayment of a loan facility with Nebari, and general working capital [2]. Group 3: Company Background - Lion One Metals is an emerging Canadian gold producer with operations at the Tuvatu Alkaline Gold Project in Fiji, which includes a high-grade gold deposit and various mining facilities [8].

Core Viewpoint - Tier One Silver Inc. has successfully completed the second and final tranche of its upsized non-brokered private placement, raising a total of C$6,500,000, which reflects strong investor interest and confidence in the company and the precious metals market, particularly silver [1][2]. Group 1: Offering Details - The second tranche involved the issuance of 39,762,000 units at C$0.08 per unit, generating gross proceeds of C$3,180,960 [1]. - Each unit consists of one common share and one full common share purchase warrant, with the warrants allowing the purchase of shares at C$0.11 for up to 36 months [1]. - The total gross proceeds from the Offering are C$6,500,000, indicating robust demand and oversubscription [1][2]. Group 2: Use of Proceeds - The proceeds from the Offering will be utilized for exploration at the Curibaya project, investigation of new projects, and general working capital [2]. Group 3: Financial Advisory and Fees - The company paid cash finders' fees of C$165,256 and issued 2,065,700 non-transferable finders' warrants to Canadian registrants, along with additional fees to a European investment firm [2]. - A corporate finance fee was paid to 3L Capital Inc., which included $140,000 in cash, 1,250,000 units, and 1,750,000 warrants, all under the same terms as the Offering [2]. Group 4: Company Overview - Tier One Silver is focused on discovering world-class silver, gold, and copper deposits in South America, with its flagship project being Curibaya [5]. - The management and technical teams have a strong track record in capital raising and monetizing exploration success [5].

Group 1 - Stonegate Capital Partners has initiated coverage on Seabridge Gold Inc. (NYSE: SA) as of September 15, 2025 [1] - As of Q2 2025, Seabridge Gold reported cash and cash equivalents of $121.4 million, bolstered by a $100.2 million equity financing in February 2025 and a $30.5 million flow-through financing in June 2025 [1] - The company is focused on advancing its flagship KSM project and exploration at Iskut, 3 Aces, and Snowstorm [1] Group 2 - Seabridge Gold renewed its $750 million base shelf prospectus and $100 million ATM facility in early 2025 [1] - The company reported a Q2 net profit of $12.3 million ($0.12/share), a decrease from $45.2 million in Q2 2024, primarily due to the remeasurement of secured note liabilities [8] - Seabridge invested $21.1 million into projects during the quarter, and drilling at Iskut's Snip North confirmed a large copper-gold porphyry deposit, with a maiden resource estimate expected in early 2026 [8]

Swansea City AFC, the second tier football team, is seeking to raise £50 million in equity to accelerate the Welsh club’s growth https://t.co/HqfQ3uTpOM ...

Core Points - Dryden Gold Corp. has successfully closed its upsized non-brokered equity financing, raising a total of $7,820,120 through the issuance of 31,721,667 common shares [1][2] - Centerra Gold Inc. exercised its 'top-up right' to maintain a 9.9% interest in Dryden Gold, as per the investor rights agreements [2] - The proceeds from the financing will be allocated to drilling and regional field work on the Dryden Gold Property, qualifying as eligible resource exploration expenses under Canadian tax laws [3] Financing Details - The financing consisted of three types of shares: 9,216,667 flow-through common shares (FT Shares) at $0.24 each, 13,180,000 charity flow-through common shares (CFT Shares) at $0.284 each, and 9,325,000 hard dollar common shares (HD Shares) at $0.20 each [1] - The total proceeds from FT Shares were approximately $2,212,000, from CFT Shares were about $3,743,120, and from HD Shares were around $1,865,000 [1] Use of Proceeds - Gross proceeds from FT Shares and CFT Shares will fund additional drilling and field work on the Dryden Gold Property, qualifying as Canadian exploration expenses and flow-through mining expenditures [3] - Proceeds from HD Shares will be used for working capital, general and administrative expenses, and marketing [3] Insider Participation - The CEO of Dryden Gold subscribed for 250,000 HD Shares, while the VP of Exploration subscribed for $50,000 worth of HD Shares [4] - The issuance of HD Shares to insiders is classified as a related party transaction, with the company relying on exemptions from formal valuation and minority shareholder approval requirements [4] Regulatory Compliance - The share issuance is subject to final acceptance by the TSX Venture Exchange and compliance with applicable regulatory requirements [5] - The financing was conducted under the Listed Issuer Financing Exemption, meaning it will not be subject to a hold period under Canadian securities laws [5]

Core Insights - TMX Group reported a significant decrease in financing activity on the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) for July 2025, with total financings raised down 68% from the previous month but up 255% compared to July 2024 [2][4]. TSX Summary - In July 2025, TSX welcomed 12 new issuers, a decrease from 25 in June 2025 and an increase from 10 in July 2024 [2][5]. - Total financings raised amounted to $1.22 billion, a sharp decline from $3.77 billion in June 2025 but a significant increase from $343.36 million in July 2024 [5]. - The total number of financings was 27, down from 55 in the previous month and up from 17 in July 2024 [2][5]. - Year-to-date statistics show 152 new issuers listed, a 76.7% increase from 86 in 2024, and total financings raised of $9.71 billion, down 8% from $10.56 billion in 2024 [6]. TSXV Summary - TSXV had one new issuer in July 2025, down from five in June 2025 and three in July 2024 [4][7]. - Total financings raised were $705.31 million, a slight decrease of 3% from the previous month but up 49% from July 2024 [4][8]. - The total number of financings was 139, compared to 100 in June 2025 and 93 in July 2024 [4][8]. - Year-to-date statistics indicate 23 new issuers listed, a decrease of 20.7% from 29 in 2024, with total financings raised of $4.02 billion, a 63% increase from $2.46 billion in 2024 [9]. Market Capitalization - The market capitalization of listed issues on TSX was approximately $5.56 trillion in July 2025, reflecting growth from $4.63 trillion in July 2024 [5][6]. - TSXV's market capitalization was around $112.08 billion, up 42.2% from $78.83 billion in July 2024 [9].

Core Viewpoint - Assembly Biosciences, Inc. has announced a registered offering of common stock and warrants, aiming to raise capital for its innovative therapeutics targeting serious viral diseases [1][4]. Group 1: Offering Details - The offering consists of 5,591,840 shares of common stock and pre-funded warrants for 1,040,820 shares, with a combined price of $19.60 per share and accompanying warrants [1]. - Each pre-funded warrant has a nominal exercise price of $0.001 and is immediately exercisable, while Class A and Class B warrants have an exercise price of $21.60 and specific expiration conditions [1]. - The offering and a private placement with Gilead Sciences, Inc. are expected to close on August 11, 2025, contingent upon customary closing conditions [4]. Group 2: Investor Participation - The offering includes participation from both new and existing investors, such as Commodore Capital, Blackstone Multi-Asset Investing, and Farallon Capital Management [2]. - Gilead will purchase 2,295,920 shares in a private placement at the same price as the offering, which will not be registered under the Securities Act [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be utilized for general corporate purposes [4]. Group 4: Company Overview - Assembly Biosciences is focused on developing small-molecule therapeutics aimed at serious viral diseases, including herpesvirus and hepatitis infections [7][8].

Dryden Gold Corp. Announces Upsizing of Previously Announced Equity Financing with Participation from Centerra Gold August 08, 2025 6:00 AM EDT | Source: Dryden Gold Corp. Vancouver, British Columbia--(Newsfile Corp. - August 8, 2025) - Dryden Gold Corp. (TSXV: DRY) (OTCQB: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company is pleased to announce that as a result of excess demand it is increasing the previously announced (July 17, 2025) non-brokered equity financing under the Listed Issuer Financing Exemption ...

Core Viewpoint - Revival Gold Inc. has successfully closed a financing round, raising approximately C$29.08 million through the issuance of common shares, enhancing its balance sheet and supporting its gold asset value for shareholders [1][3]. Financing Details - The financing consisted of a strategic non-brokered private placement with EMR Capital Management Limited, which subscribed for 32,069,531 common shares at C$0.48 per share, totaling gross proceeds of approximately US$11.3 million (C$15.4 million) [2]. - A concurrent non-brokered private placement involved the issuance of 28,517,502 common shares at the same price, generating gross proceeds of C$13.68 million [2]. - Post-financing, EMR and Dundee Corporation hold approximately 11.8% and 5.3% ownership in Revival Gold, respectively [2]. Strategic Implications - The financing was structured to be favorable to existing shareholders, avoiding debt and not compromising future strategic flexibility [3]. - EMR has been granted the right to nominate one director to the board and has customary anti-dilution rights [4]. Leadership Changes - Tony Manini, a geologist with over 35 years of experience, has been appointed as a director following EMR's investment, while former director Norm Pitcher transitions to a senior advisory role [5][6][7]. Use of Proceeds - The net proceeds from the offerings will be allocated to advancing the exploration and development of the Mercur and Beartrack-Arnett projects, as well as for general working capital and corporate purposes [9]. Regulatory Compliance - The common shares issued under the concurrent offering are exempt from hold periods under applicable Canadian securities laws, while those from the EMR placement are subject to a 4-month and one-day hold period [8][9].